Milestones

05 Capital injection for NT$ 964,903,710 and exercise of employee stock options for NT$194,700 respectively
03 The stock was officially listed on the Securities TPEx Trading Center.

12 US FDA has granted orphan drug designation to L608 for the treatment of Systemic Sclerosis (SSc)
12 The Ministry of Economic Affairs has approved and issued a letter for the biotechnology new drug investment project "L608," allowing shareholders to benefit from tax deductions under the Biotechnology and New Pharmaceuticals Industry Development Act.
11 Exercise of employee stock options for NT$2,204,000
09 Capital injection for NT$360,000,000
08 L608 (liposomal-iloprost), obtained the approval of the Australian HREC to conduct the Phase I clinical trial, and has been acknowledged by the Australian TGA for Clinical Trial Notification (CTN).
07 Exercise of employee stock options for NT$2,253,900
06 Pharmosa announced the collaboration with Liquidia Technologies, Inc. For L606 in North America
03 L606 submitted the Phase 3 study protocol amendment to the US FDA to expand the enrolled patient population

12 Capital injection for NT$494,000,000 and exercise of employee stock options for NT$1,419,000 respectively
02 Successfully enlisted in Emgerging Market; Stock Code: 6875

11 Obtained approval for Public Status Registration with Securities and Futures Bureau, Financial Supervisory Commission; Stock Code: 6875
10 Capital injection for NT$300,000,000 and exercise of employee stock options for NT$66,040,000 respectively
08 L606 launched phase III pivotal trial in US
01 Capital injection for NT$486,978,000

10 L606 received subsidies from the "A+ Industrial Innovative R&D Program - Fast Track Clinical Trial Program" sponsored by MOEA.
09 L606 received last patient in for phase I clinical trial
07 Changed face value to NT$5 per share (face value was originally at NT$10 per share)
05 Capital injection of NT$25,000,000
04 L606 received first patient in for phase I clinical trial
04 Capital injection of NT$25,000,000
03 L606 launched Phase I clinical trial in US
01 L606 received FDA approval for Phase I study

12 Received qualifying status for our investors to receive Tax Incentive from investment per the “Act For The Development of Biotech And New Pharmaceuticals Industry” governed by MOEA, R.O.C.
09 Capital injection for NT$50,000,000
05 Submission of USPTO provisional application (application No.: 62667889 and 62670875)

10 Received Government grant funded by MOEA
07 Submission of USPTO provisional application (application No.: 62536034 and 62595207)

10 Renamed company to “國邑藥品科技股份有限公司” in Chinese & “Pharmosa Biopharm Inc.” in English
10 Re-locating headquarter from Taichung to Nangang Software Park III, Nangang District, Taipei City
05 Focusing on new drug development through the 505(b)2 pathway

Pharmosa Limited (a predecessor of Pharmosa Biopharm Inc.)

Recognized as a "Biotech and New Pharmaceutical Company" by the Act For The Development of Biotech And New Pharmaceuticals Industry, governed by Ministry of Economic Affairs (MOEA), R.O.C.
Licensing various Gx Products to Anxo Pharma
M480384 patent granted in Taiwan and China
2010, Setup of R&D Center in Nangang Software Park III, Nangang District, Taipei City
2000, Pharmosa Limited founded in Taichung.

D e l i v e r H o p e f o r a B e t t e r L i f e